Department of Gynaecology, Charité - Campus Virchow-Klinikum, Berlin University Medicine, Berlin, Germany.
Anticancer Res. 2012 Sep;32(9):3969-76.
We describe the impact of a sequential dose-dense schedule of carboplatin and paclitaxel on the quality of life (QoL) of patients with ovarian cancer.
In this multicenter phase II trial, four cycles of carboplatin followed by 12 cycles of weekly paclitaxel were applied after cytoreductive surgery. QoL was assessed using the QoL questionnaires EORTC QLQ-C30 and QLQ-OV28 before chemotherapy (baseline), after four cycles of carboplatin, at the end of treatment (EOT), and after 6, 12, and 24 months.
Out of 104 eligible patients 87 (84%) participated in at least one QoL assessment. At baseline, all QLQ-C30 scales and symptoms were significantly worse than age-adjusted values for the general population. Subsequently QoL improved in general. During chemotherapy with paclitaxel, most functioning scales and symptoms worsened slightly (not significantly). However, peripheral neuropathy and chemotherapy-related side-effects increased to clinically important levels. At the end of treatment, most QoL scores were similar to those of the general population, but physical functioning and fatigue were worse. Sexual functioning and peripheral neuropathy remained problematic.
QoL was affected mainly by the weekly paclitaxel schedule, but effects were in most cases only temporary. A dose-dense regimen using a sequential protocol may be favourable in terms of QoL.
我们描述了卡铂和紫杉醇序贯剂量密集方案对卵巢癌患者生活质量（QoL）的影响。
在这项多中心 II 期试验中，在细胞减灭术后应用 4 个周期的卡铂，随后是 12 个周期的每周紫杉醇。使用 EORTC QLQ-C30 和 QLQ-OV28 问卷在化疗前（基线）、卡铂 4 个周期后、治疗结束时（EOT）以及 6、12 和 24 个月后评估 QoL。
在 104 名合格患者中，87 名（84%）至少参加了一次 QoL 评估。基线时，所有 QLQ-C30 量表和症状均明显差于一般人群的年龄调整值。随后 QoL 总体上有所改善。在紫杉醇化疗期间，大多数功能量表和症状略有恶化（无统计学意义）。然而，周围神经病变和化疗相关副作用增加到临床重要水平。治疗结束时，大多数 QoL 评分与一般人群相似，但身体功能和疲劳更差。性功能和周围神经病变仍然存在问题。
QoL 主要受每周紫杉醇方案的影响，但大多数情况下影响是暂时的。使用序贯方案的密集剂量方案可能在 QoL 方面具有优势。
